Evidence map›Paper›PMID 33746987›Full record

Trial reportFrontiers in immunology2021

Antiretroviral Treatment-Induced Decrease in Immune Activation Contributes to Reduced Susceptibility to Tuberculosis in HIV-1/Mtb Co-infected Persons.

Katalin A Wilkinson, Deborah Schneider-Luftman, Rachel Lai, Christopher Barrington, Nishtha Jhilmeet, David M Lowe, Gavin Kelly, Robert J Wilkinson

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Early innate cell interactions withFrontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Katalin A WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London, United Kingdom.
Deborah Schneider-LuftmanBioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.
Rachel LaiDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Christopher BarringtonBioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.
Nishtha JhilmeetWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
David M LoweWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Gavin KellyBioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.
Robert J WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London, United Kingdom.
The Francis Crick Institute · GBUniversity of Cape Town · ZAImperial College London · GBWellcome Centre for Infectious Diseases Research in Africa · ZA

Funding

Cancer Research UK FC001218Wellcome Trust 087754Wellcome Trust 104803Wellcome Trust 203135Wellcome Trust FC001218
6 · The paper itself

Abstract

Antiretroviral treatment (ART) reduces the risk of developing active tuberculosis (TB) in HIV-1 co-infected persons. In order to understand host immune responses during ART in the context of

Indexed as

HIV InfectionsRNA-SeqAdultAnti-Retroviral AgentsCoinfectionCytokinesDisease SusceptibilityFemaleHIV-1HumansLatent TuberculosisLongitudinal StudiesMaleMiddle AgedMycobacterium tuberculosisAnti-Retroviral AgentsCytokinesantiretroviral treatmentplasma biomarkerQuantiFERONRNAseqtuberculosis

Identifiers

PMID33746987
PMCPMC7973093
OpenAlexW3098027462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.